ArticleAmerican journal of translational research2023
Fucoxanthin suppresses the malignant progression of ovarian cancer by inactivating STAT3/c-Myc signaling.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Natural compounds targeting glycolysis and TME in ovarian cancer: from metabolic crosstalk to therapeutic potential.Frontiers in pharmacology · 2026Review
- Discovery of Anoikis-correlated Biomarkers for Ovarian Cancer Through Integrated Transcriptome and Single-cell RNA Sequencing Analyses.Current topics in medicinal chemistry · 2026Article
- Fucoxanthin fromMarine drugs · 2025Article
- Salidroside exerts anti-tumor effects in ovarian cancer by inhibiting STAT3/c-Myc pathway-mediated glycolysis.Biomolecules & biomedicine · 2024Article
- Fucoxanthin Inhibits Development of Sigmoid Colorectal Cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals.Cancer genomics & proteomics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOvarian cancer is a frequent malignancy among women. Fucoxanthin has been discovered to exert anti-tumor impacts on numerous tumors. Herein, the current work was carried out to identify the biological function of fucoxanthin on the malignant progression of ovarian cancer and to explore the underlying molecular mechanisms.
methodsIn this study, cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU) staining, wound healing, as well as transwell assays were employed to assess the malignant cell phenotypes, including cell proliferation, migration and invasion in ovarian cancer. The expression of related proteins was evaluated using western blot. Additionally, the glucose uptake, intracellular adenosine triphosphate (ATP), extracellular acidifications rates (ECAR) and glycolysis-associated enzymes were measured to evaluate glycolysis level.
resultsIt was demonstrated that fucoxanthin restrained the proliferative, migratory and invasive capabilities in both A2780 and OVCAR3 cells. Fucoxanthin could inhibit glycolysis and inactivate signal transducers and activators of transcription 3 (STAT3)/c-Myc signaling. In addition, Colivelin, a STAT3 activator, greatly weakened the suppressive effects of fucoxanthin on ovarian cancer cell proliferation, migration, invasion and glycolysis.
conclusionFucoxanthin exerts anti-tumor activity in ovarian cancer, possibly via inactivation of the STAT3/c-Myc signaling pathway, and thus provides a novel therapeutic strategy for the treatment of ovarian cancer.
Indexed as
Identifiers
37193140PMC10182483W4376870990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.